A First-In-Human Trial of pTTL in Advanced Colorectal Cancer
Status:
Recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomised FIH trial investigating the safety and tolerability of
a novel ATMP, pTTL, composed of autologous tumour-draining lymph node-derived T cells
stimulated in vitro with personalised cancer neoantigens.
The neoantigens are selected through a process starting with next generation sequencing (NGS)
of tumour material from the patient followed by selection of neoantigenic mutations using an
in-house software, PIOR®. Selected neoantigen epitopes are expressed as recombinant proteins,
NAG, and used to stimulate T cells to promote neoantigen-specific T cell expansion in vitro
in pTTL production.
pTTL is thus based on autologous cells stimulated with patient-specific neoantigens. In
consequence, every pTTL product is unique and designated for use in one single individual.
pTTL will be administered to patients with stage IV colorectal cancer (CRC) as a single
intravenous dose.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Neogap Therapeutics AB
Collaborators:
CTC Clinical Trial Consultants AB Karolinska University Hospital Region Västmanland Vecura